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(TCRs) and chimeric antigen receptors (CARs) has shown 
its potential. A valuable addition to ‘engineered’ adap-
tive immunity has emerged recently through the improved 
understanding of how innate immune cells can attack can-
cer cells without substantial side effects. This has enabled 
the development of transplantation platforms with limited 
side effects allowing early immune interventions as well as 
the design of engineered immune cells expressing innate 
immune receptors. Here, we focus on innate immune 
interventions and their orchestration with TCR- and CAR-
engineered immune cells. In addition, we discuss how the 
exploitation of the full potential of cellular immune inter-
ventions is influenced by regulatory frameworks. Finally, 
we highlight and discuss substantial differences in the 
current landscape of clinical trials in Europe as compared 
to the USA. The aim is to stimulate international efforts 
to support regulatory authorities and funding agencies, 
especially in Europe, to create an environment that will 
endorse the development of engineered immune cells for 
the benefit of patients.
Keywords Allogeneic stem cell transplantation · Innate 
immune system · Gene therapy · CIMT 2014 · Phase I/II 
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Abstract Over half a century ago, the first allogeneic 
stem cell transplantation (allo-SCT) initiated cellular 
immunotherapy. For several decades, little progress was 
made, and toxicity of allo-SCT remained a major chal-
lenge. However, recent breakthroughs have opened new 
avenues to further develop this modality and to provide 
less toxic and equally efficient interventions for patients 
suffering from hematological or solid malignancies. Cur-
rent novel cellular immune interventions include ex vivo 
expansion and adoptive transfer of tumor-infiltrating 
immune cells or administration of drugs which antagonize 
tolerizing mechanisms. Alternatively, transfer of immune 
cells engineered to express defined T cell receptors 
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Introduction
With the first allogeneic stem cell transplantation (allo-
SCT) more than 50 years ago, a new era of therapeutic 
intervention was born, namely cellular immunotherapy. 
In particular, donor lymphocyte infusions (DLI) provided 
early and important insights into the potency and mode of 
action of immunotherapy, as it has the potential to induce 
sustainable remissions even in patients with advanced 
hematological malignancies. Also, solid malignancies can 
be targeted by T lymphocytes, both from an allogeneic 
stem cell source [1] and by endogenously derived tumor-
infiltrating lymphocytes (TIL) [2]. Analyzing failure and 
success of immunotherapies in hematological malignan-
cies, and in solid cancers, frequently elucidated the same 
requirements for an efficient therapy, i.e., the immune sys-
tem seems to be most effective when mounting a complex 
immune response against a defined intruder. Yet, limiting 
immune interventions to one or two antigens in therapeutic 
interventions may increase the likelihood of tumor escape. 
This might explain the success of allo-SCT and TILs but 
also the recent clinical success of antibodies designed to act 
on inhibiting regulatory components of the immune sys-
tem such as anti-PD1 or anti-CTLA4 [3], [4]. However, as 
‘releasing the brake’ from all T cells does not only affect 
tumor-specific immune responses, unwanted ‘off-target’ 
reactivity is frequently observed, like graft-versus-host 
disease (GVHD) or immune-related side effects [4]. Con-
sequently, ideal future designs of immune therapeutic inter-
ventions should broaden tumor antigen-specific immune 
responses, but without substantial toxicity.
A recent and promising intervention is the controlled 
enlargement of the immune repertoire by transferring tumor 
specificity. This transfer is accomplished by redirecting T 
cells with a receptor-recognizing defined antigens on a can-
cer cell [5]. Receptors explored to date have been either iso-
lated from cancer reactive αβT cells [6] or engineered by 
fusing tumor-reactive antibodies with signaling domains of 
T cells, so-called chimeric antigen receptor (CAR) [7]. Land-
mark clinical trials with an TCR specific for MART-1 mel-
anocyte differentiation antigen [8] or an anti-CD19 CAR [9] 
have shown the great potential of this approach, leading to 
an impressive number of ongoing clinical trials (Table 1 and 
Supplementary Table 1 insert ‘in ESM’). However, the num-
ber of antigens that can be safely targeted in patients is—at 
least at this stage—still relatively limited. In this view, the 
transfer of an alternative set of immune cells and receptors 
will be discussed. This includes the prospects of ‘low-GVHD’ 
transplantation protocols, based on the preservation of innate 
immune cells early after transplantation, which can serve as 
platform for additional immune interventions, as well as the 
transfer of immune cells designed to express highly selected 
(innate) immune receptors originated from the innate immune 
system such as NKG2D or γδTCRs (reviewed in detail [10]). 
These innate receptors are a less utilized type of immune 
receptors but possess some appealing and unique advantages 
as compared to TCRs and CARs. Finally, the prospects and 
limitations of broadening the application of this exciting and 
potent therapeutic strategy are discussed.
Innate allo‑SCT as a novel immune platform 
for early immune interventions
Allo-SCT substantially increases the overall survival for 
many patients with high-risk hematological diseases. Nev-
ertheless, the outcome for most patients is still poor, due to 
the high risk of developing severe life-threatening GVHD, 
Table 1  Ongoing clinical trials with TCR- or CAR-modified T cells
Targeted antigens Stem cell source Number of trials in USA Number of trials in EU
TCR based (n=13) NY-ESO-1 (n=6); MAGE-A3 (n=2); 





CAR based (n=52) CD19 (n=27); GD2 (n=4); mesothelin 
HER2 (n=3); miscellaneous (n=14)
Autologus (49);  
allogenic (4)
47 5
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encountering relapse, or substantial long-term toxicity with 
a reduced quality of life. Adoptive transfer of genetically 
modified T cells with a tumor-specific TCR is therefore an 
attractive strategy to skew the T cell compartment toward a 
more defined anti-tumor repertoire post-allo-SCT [11]. As 
such, there is a need for less toxic transplantation regimens 
which have a substantially reduced incidence of GVHD, 
do not require long-term immune suppression, and allow 
for early additional immune interventions. This may be 
achieved by separating the initial engraftment of stem cells 
from the application of immune cells via partial or com-
plete removal of immune cells from the allograft prior to 
transplantation (Fig. 1). These transplantation strategies, 
with either a delayed endogenous T cell reconstitution or a 
T cell add back via DLI, have resulted in a decreased trans-
plantation-related mortality (TRM) due to a lower inci-
dence of GVHD, as compared to T cell replete allo-SCT 
[12]. This is a consequence of separation of the inflamma-
tion mediated by the required conditioning from the infu-
sion of αβT cells. For instance, in a recent prospective and 
randomized phase III clinical trial, Pasquine et al. [13] have 
demonstrated that complete elimination of immune cells by 
enrichment of the CD34+ cells lowers long-term morbid-
ity as a result of a substantially reduced chronic GVHD, 
without negatively impacting relapse rates in patients with 
acute myeloid leukemia (AML). Selective depletion of αβT 
cells has been suggested as an alternative approach [14]. 
This strategy maintains NK cells and γδ T cells in the graft, 
which have an intrinsic activity against tumors and infec-
tions, without detrimental reactivity toward healthy tissue 
[10]. As this regimen favors the early reconstitution of the 
innate immune system, such a strategy should theoretically 
result in an improved control of the tumor and infections. 
The feasibility of such an approach has been shown most 
recently by Bettiana et al. [15], in which 23 children with 
non-malignant disorders received a HLA-haploidentical 
hematopoietic stem cell transplantation (haplo-HSCT) after 
ex vivo elimination of T cells and CD19+ B cells. In this 
cohort, none of the patients developed a GVHD ≥grade 
III, and the cumulative incidence of TRM was 9.3 %. How-
ever, the impact on malignancies could not be assessed, as 
only those patients with benign disorders received trans-
plantations. Currently, T cell depletion (Fig. 1) is evaluated 
both in the setting of haplo-SCT and in the MRD/MUD 
in patients suffering from hematological malignancies. A 
potential drawback of these strategies is that innate immune 
system reconstitution early after transplantation is very 
diverse and does not necessarily contain all the components 
required to control tumors and infections (for review see 
[16]). In addition, even with an optimally selected donor, 
the innate immune system quickly becomes accustomed 
to its new host environment (education), resulting most 
CD 3 depleon OR
CD34 selecon






Fig. 1  Low GVHD allo-SCT platforms can be achieved by complete 
removal of the T cell repertoire via CD34+ selection [13] (upper 
part). Alternatively, a so-called innate allo-SCT can be generated by 
specific removal of T cells from the graft, rendering γδT cells and NK 
cells within the leukapheresis product (lower part) [14], [15]
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likely in a loss of efficacy of the innate donor immune sys-
tem after a couple of months post-allo-SCT [17]. This cre-
ates the need for additional immune interventions that do 
not increase GVHD after an innate allo-SCT, in particular 
within the context of poor risk hematological malignancies, 
for which the race against relapse is difficult to win, and 
GVHD remains a substantial threat.
Moving from DLI to genetically engineered T 
cells: aiming for a diverse repertoire with multiple 
and complementary defined receptors
To date, the most potent immune intervention after allo-
SCT is a DLI. DLI has already for some decades been 
appreciated as a curative treatment in relapsing disease 
after allo-SCT, especially in patients with chronic mye-
loid leukemia, and to a lesser extend for AML [18], [19]. 
Also for hematological diseases, originally thought to be 
less sensitive to DLI—like acute lymphoblastic leukemia 
(ALL) and multiple myeloma (MM)—some recent reports 
have shown a beneficial effect of DLI [20], [21]. Effects are 
usually observed 4–6 weeks post-application, after doses 
administered with a range between 1 × 105 and 1 × 107 
T cells per kg. However, a DLI does not always provide 
tumor control, and DLI can be associated with substantial 
GVHD. Again the unpredictable diversity in the repertoire 
of a DLI is the major hurdle, given that the dose of the 
tumor-reactive T cells within the DLI is most likely just a 
fraction of the total T cell pool, as the frequency of allo-
reactive T cells is reported to be between 1–10 % [16].
In order to further increase efficacy of a DLI while 
reducing toxicity, limitation of the diversity of transferred 
cells is needed. Most likely, relatively low doses will be 
sufficient, given they have the correct specificity and are 
available within a defined immunological subtype which 
can expand, contract, and provide long-term memory. In 
addition, some variety must be preserved to allow a diverse 
repertoire to tackle cancer cells at different targets and to 
prevent tumor escape mechanisms, such as antigen loss. 
This goal can potentially be accomplished by taking advan-
tage of T cells genetically engineered to express a single 
or a variety of diverse tumor-specific immune receptors 
(Fig. 2a). Already over a decade ago, it has been demon-
strated in animal models that the specificity of a T cell 
can be transferred between T cells by introduction of and 
TCR genes [22]. These and other observations have been 
translated to the first series of clinical trials with TCR-
transduced T cells with different target antigens for solid 
malignancies [23]. Tumor-reactive TCRs were classically 
either isolated from TILs, from peripheral blood of patients 
responding to immune therapy (MAGE vaccination stud-
ies for instance), or from mouse origin. As a consequence, 
isolated anti-tumor TCRs are restricted toward a limited 
pool of HLA molecules. To further extend this method to 
have broader application, it may be technically feasible 
to generate cellular products harboring multiple tumor-
specific immune receptors extracted from a given patient. 
With innovative techniques, in which the cancer exome is 
analyzed in a high throughput fashion [24], it is now pos-
sible to identify tumor-specific T cells directed against 
unique tumor antigens in individual patients [25] and as 
such fully exploit the cancer ‘antigenome’ and overcome 
HLA barriers. In addition to neo-antigen TCR transfer, 
novel treatment concepts may arise from identifying highly 
abundant TCR pairs from TILs, as they seem to be enriched 
for tumor mutation-specific antigens (unpublished data pre-
sented by S. A. Rosenberg at AACR 2014 in San Diego). 
Although transfer of neo-antigen-specific TCRs and TCR 
gene capture may bear a huge potential, such a personal-
ized treatment concept will face major medical, regulatory, 
logistical, and financial challenges, as it creates the need to 
individualize genetic engineering to multiple (known and 
unknown) targets varying for every given patient.
CARs—which can be applied irrespective of HLA 
type—seem a highly attractive alternative for clinical 
implementation by pharmaceutical companies. The first 
clinical studies with a CD19-specific CAR have shown 
very promising results in ALL [26] and CLL [9] and led 
to an impressive amount of clinical trials (Table 1 and 
reviewed in [27]). The results of these studies will provide 
valuable information which is likely to contribute to the 
improvement in cellular therapy. However, the number of 
antigens for which antigen-specific receptors are tested in 
current clinical trials is frequently redundant and thus very 
limited (as shown in Table 1). To expand cellular therapy to 
a broader range of tumors or to enlarge the TCR- or CAR-
redirected T cell repertoire, alternative targets and receptors 
are needed. Receptors of the innate immune system might 
provide an interesting alternative (Fig. 2) [10], [16].
Innate immune receptors with unique features 
leading to comprehensive tumor recognition
Natural killer (NK) cells are the most widely studied sub-
set of innate immune cells in the context of anti-tumor 
responses. NK cells express an array of activating and 
inhibitory receptors, which collectively discriminate 
healthy cells from diseased cells by sensing self-‘stress’ 
molecules on diseased target cells, including tumor cells 
[28]. NKG2D is the best known of these receptors. NKG2D 
recognizes stress-induced self-MHC class I-related pro-
teins, which have a selectively increased surface expression 
on transformed cells from both hematological and solid ori-
gins [29]. To harness NK cell-mediated toxicity, chimeric 
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receptors linking NKG2D to the cytoplasmic domain of 
CD3ζ have been constructed, and T cells equipped with 
such an NKG2D receptor display anti-tumor reactiv-
ity in both hematological and solid tumor models [30]. 
Also, bi-specific antibodies of a NK cell receptor fused to 
a single-chain fragment have shown tumor reactivity in 
various tumor models [31]. Inhibitory receptors impede 
NK cell reactivity by sensing the presence of MHC class 
I molecules constitutively expressed on almost all healthy 
cells. Killer cell immunoglobulin-like receptors (KIRs) are 
a well-studied example of such inhibitory molecules. For 
example, it has been reported that NK cells can kill allo-
geneic cells when their inhibitory KIRs are not engaged 
due to mismatched HLA alleles [32]. Two recent phase I 
studies in AML [33] and MM [34] have shown that an anti-
KIR antibody can be safely administered to patients, and as 
such, full KIR saturation can be achieved, supporting sub-
sequent trials to test for clinical activity.
Following NK receptors, the γδTCR has recently drawn 
attention as an alternative anti-tumor immune receptor 
Fig. 2  a Utilization of T cell 
receptors, T cell receptors, 
CARs, and NK cell receptors 
to transfer desired immune 
specificities to donor T cells. 
TAA tumor associated antigen. 
b Toolbox of immune receptors, 
vectors for gene transfer, and 
carrier cells that can be com-
bined with each other to treat 
different malignancies
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with some unique appealing features (reviewed in [10]). 
γδ T cells express a somatically recombined γδ TCR, but 
behave like innate cells in a way that they—like NK cells 
–become activated by ‘stressed cells,’ The γδTCR is just 
one of the multiple proteins on the surface of a γδ T cell 
which can sense molecular stress signatures. A significant 
subset of γδ T cells express a TCR composed of V9 and V2 
chains, which can recognize multiple targets on malignant 
cells, such as the complex of apolipoprotein A1 (ApoA1) 
and F1-ATPase. In addition, they can sense accumulated 
non-peptidic pyrophosphate molecules (phosphoantigens), 
intermediates of a deregulated mevalonate pathway of iso-
prenoid synthesis, via BTN3A1 (CD277). As such, γ9δ2T 
cells can mount immune responses against tumor cells 
derived from both hematological and solid malignancies 
[35], [36]. Unfortunately, translating these in vitro observa-
tions into effective clinical protocols remains challenging, 
since—despite substantial evidence in vivo in mice [37]—
adoptively transferred autologous γδ T cells demonstrate 
anti-tumor reactivity only at modest and variable response 
rates [16]. The moderate success of these responses seems 
to be critically determined by the composition of the γδ T 
cell repertoire. Diversity in the γδTCR as well as the co-
receptor repertoire leads to a diverse function and activa-
tion status of an individual γδ T cell. This makes ‘the γδ 
T cell repertoire’ a very heterogeneous population with 
anti-tumor activity that is difficult to predict. For instance, 
in vitro analysis of individual γ9δ2T cell clones revealed a 
highly differential anti-tumor reactivity [38], which did not 
appear to be explained by the different repertoire of inhibi-
tory and activating receptors on individual cells [39], but by 
the small variations in the CDR3 region of the γ9δ2 TCR 
[38].
Therapeutic concepts with engineered ‘innate receptors’ 
fall in two categories: single proteins and membrane-bound 
receptors, and both may complement other types of cellular 
therapies. For instance, NKG2D fused to anti-CD3 variable 
fragment (scFv-NKG2D) has been shown to engage tumor 
cells with T cells [34]. Also antibodies directed against 
KIRs (see above) and soluble MHC class I-related pro-
tein A (sMICA; a ligand for NKG2D which in its soluble 
form is associated with NK inactivation) have been dem-
onstrated to stimulate T cell-specific responses [40]. Con-
comitant administration of such proteins, with DLI or an 
engineered cellular product, may very well result in syn-
ergistic responses. The group of membrane-bound engi-
neered innate receptors can either consist of (optimized) 
wild-type protein [38], fusion proteins (CARs) or single-
chain receptors. Transfer of such receptors into T cells may 
complement attractive features of both the innate and adap-
tive immune system. T cells are easy to collect and are fully 
equipped to proliferate and activate upon antigen recogni-
tion. The introduced innate receptor is not MCH-restricted. 
In addition, the formation of mixed dimers does not occur. 
As such, a cellular product can be engineered containing 
sufficient numbers of effector cells with desired and uni-
form specificity.
For example, our group is preparing a phase I trial for 
γδTCR gene transfer. To ‘pick the most effective γδTCRs’ 
for future clinical applications, we have developed the 
‘combinatorial γδTCR chain exchange.’ This allows for 
selection of the γ9δ2TCRs with the highest affinity [38]. 
Like their counterparts, γδTCR genes can be retrovi-
rally transduced into both CD4+ and CD8+ T cells. These 
γδTCR-engineered T cells can recognize a broad panel 
of tumor cell lines both in vitro and in vivo as well as a 
variety of primary AML blasts, but they ignore non-trans-
formed cells [41]. Interestingly, introduction of the γδTCR 
leads to down-regulation of the endogenous TCR, likely 
due to competition for components of the CD3 complex. 
This competition can be used to negatively select non-engi-
neered cells with TCR bright cells from a transduced T cell 
bulk, resulting in an end product containing almost 100 % 
γδTCR-engineered T cells with increased anti-tumor func-
tion in vitro as well as in vivo (Straetemans et al, unpub-
lished data). These results have led to the design of the first 
clinical trial in which γδ TCR-engineered T cells will be 
tested in patients with AML, who will receive an T cell-
depleted stem cell transplantation from a MRD/MUD 
(Fig. 1) followed by an infusion of γδ TCR-engineered T 
cells 3–6 months post-allo-SCT.
A space of endless choices: How to develop the 
best cellular immunotherapy?
Further work is needed to establish genetically modified T 
cells as a widely accepted mode of treatment for hemato-
logical malignancies. Preclinical and small phase I stud-
ies—in the past mainly initiated by academic institutions, 
but now increasingly promoted by young and innova-
tive biotech companies—are essential to broaden existing 
concepts and to develop new concepts. While the field is 
moving from allo-SCT to more engineered cellular prod-
ucts that are enriched for anti-tumor activity and depleted 
of unwanted cross-reactive T cells, many challenges remain 
for the translation of novel concepts from the lab to the 
clinical setting.
Engineered cellular therapies constitute a new class of 
products that on one hand bear a huge potential for benefit 
(as shown by unprecedented effect sizes in a large fraction 
of treated patients) but on the other hand bear a risk of seri-
ous (even fatal) side effects [42]. As outlined above, ear-
lier progress in science and technologies has equipped us 
with a huge toolbox of immune receptors, vectors for gene 
transfer, and carrier cells that can now be combined with 
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each other (or with additional non-cellular compounds) in 
multiple ways and therefore give rise to countless differ-
ent permutations of products for the treatment of various 
hematological and solid cancers (Fig. 2b).
Altering one component of the toolbox could lead to 
increased benefit or increased toxicity (or both) for patients. 
Due to the species specificity of antigen expression, antigen 
processing, antigen presentation, and immune recognition, 
the available non-clinical in vivo models are not predictive 
for the outcome in patients [43]. Although non-clinical in 
vitro studies to predict off-target cross-reactivity have been 
proposed [44], it is clear that the final answers can only be 
obtained in clinical trials. A researcher may feel inclined 
to utilize an empiric approach and iteratively test multi-
ple permutations in a series of small-scale trials, to iden-
tify the more toxic products as early failures and to select 
the best therapies for advanced clinical testing. Given that 
each permutation of the tool box is considered as a novel 
compound, and due to the high regulatory requirements 
associated with clinical testing of each permutated product, 
the described “empiric approach” will simply not be feasi-
ble. Due to limitations in time and available resources, this 
approach will only allow testing of one (or very few) per-
mutations in the clinic.
In this light, the existing regulatory framework requires 
a lively discussion of the field on what might be done to 
facilitate the access to innovative cellular therapies with-
out increasing the risk for patients. Some investigators 
have raised the criticism that the field of cellular immuno-
therapy (in particular therapies that include engineering 
of lymphocytes with TCRs or CARs) is sometimes held to 
higher standards as compared to other and more established 
groups of products. One seemingly well documented exam-
ple is the requirement to test for replication competent ret-
rovirus (RCR) which sponsors have to do on the master cell 
banks, retroviral supernatant lots as well as on the actual T 
cell product [45]. FDA guidelines further require follow-up 
analysis for RCRs to be performed at 3, 6, and 12 months 
and yearly following treatment. The required RCR testing is 
labor-intensive, costly, and time consuming, which limits the 
translation of such innovative approaches. Currently, avail-
able data from more than 500 patient-years of clinical imple-
mentation did not show any evidence for secondary malig-
nancies due to insertional mutagenesis form retroviral gene 
transfer to lymphocytes in patients [46]. It seems difficult 
to understand why developers of gene/cell therapies have 
to meet this high level of testing requirements despite the 
availability of decade-long safety experience, while chemo-
therapeutic agents that have a documented rate of induction 
of secondary malignancies may be used in thousands of 
patients every day without similar testing requirements. In 
addition, there is great uncertainty how to best design non-
clinical programs to support clinical trial applications. Given 
the potentially low predictive value of animal models and 
the availability of an increasing repertoire of in vitro tests to 
predict potential toxicity in humans (e.g., alanine scans for 
novel TCRs or use of complex tissue cell cultures), now may 
be the time to delineate minimum requirements for non-clin-
ical programs that both developers and regulators may agree 
upon. Such efforts cannot be achieved by single investigators 
but require field-wide efforts and a consensus process that 
can only happen in larger networks with broad representa-
tion of the different stakeholders.
Challenges are even more complex when considering the 
novel personalized treatment concepts with patient-specific 
neo-antigen-specific TCRs and TCR genes captured from 
TILs. These strategies can be regarded as personalized ther-
apies (similar to mutanome vaccines) where the specificity 
of the drug product will change between patients [47]. If the 
same regulatory requirements for these personalized prod-
ucts are applied as for defined products, these new treat-
ment concepts will never become feasible. Thus, a novel 
regulatory blueprint is needed for such personalized TCR 
approaches. A first justification for a less stringent handling 
of such personalized products could arise from the posi-
tion that (similar to a DLI) no new specificity is added to 
the immune system. Still, a series of unresolved regulatory 
questions exists and needs to be solved prior to testing these 
novel therapies in the clinic. As mentioned earlier, the delin-
eation of applicable principles for such a novel and disrup-
tive type of personalized medicine needs to be accomplished 
through scientific discussions among the various stakehold-
ers and incorporates a balance between the patient’s interest 
for safe but also timely access to novel treatments. A similar 
strategy has also been proposed to define a first regulatory 
blueprint for mutanome vaccines [47].
In summary, there is an urgent need for innovative 
strategies to reduce the amount of time and resources for 
bringing a novel cell therapy into the clinic without inap-
propriately increasing the risk for patients. Such strategies 
would allow for testing more combinations of novel tech-
nologies and realization of their full potential. We propose 
to enter an open discussion about the generation of flexible 
regulatory frameworks tailored to the unique properties of 
immune receptor-engineered cells. The major challenge 
will be to balance the need for safety within the context of 
urgent medical need, which requires continuous innovation.
A tenfold difference in clinical trials 
with genetically engineered T cells,  
what is causing the gap?
To determine which types of products are currently devel-
oped, a literature search was performed for ongoing clinical 
trials with TCR- or CAR-modified T cells. We identified an 
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encouraging number of 65 studies, of which only a disap-
pointing 10 % were enlisted in the European Union (EU) 
(Table 1). The remaining 90 % were listed in the USA.
One may only speculate on the reasons for this striking 
difference. Critical success factors that are often discussed 
but that never seem to be systematically addressed are large 
clinical/academic infrastructures, access to funding for 
innovation not only in the early stage but also for clinical 
trials, and concentration of talent which typically moves 
to the most attractive environments. Regarding the first, a 
variety of lists are published yearly, ranking the top univer-
sities around the world. The bulk of the top 10 is situated in 
the USA. Many of the currently developed cellular immu-
notherapies emerged from large institutions such as the 
NIH, the University of Pennsylvania, or the MD Anderson 
Cancer center that combine access to patients, scientific 
infrastructure, medical expertise, manufacturing capacities, 
and funding opportunities in a way that is difficult to match 
at most European institutions which are much smaller in 
size. Comparing (financial) resources between the USA and 
Europe seems virtually impossible as well. Within Europe, 
many national and international governmental, private, and 
commercially sponsored programs exist. As an example, 
since 1984, the European Commission has launched seven 
framework programs, which are dedicated to research 
and innovation. Since 1998, 351.1 million EUR has been 
donated to programs involving gene therapy projects [48]. 
This year, the eighth framework program Horizon 2020 
opened, which is the biggest EU research and innovation 
program ever, with nearly 80 billion of funding available 
over 7 years up to 2020. It aims to secure Europe’s global 
competiveness by ensuring that Europe can produce world-
class science, remove barriers to innovation, and make it 
easier for the public and private sectors to work together in 
delivering innovation. However, as impressive as the num-
bers might be at a first sight, initiatives like these seem very 
modest when compared to resources available in the USA, 
where young and innovative companies such as Juno or 
Kite can raise several hundred million dollars within a very 
short time. Another example is the number of family foun-
dations in the USA that has grown from about 3200 in 2001 
to more than 40,000 in 2015, with total annual grants for 
academic research and translation of more than $21.3 bil-
lion, according to the Foundation Center. In the USA, fed-
eral tax breaks encourage the funding through foundations, 
which give philanthropists more control over their dona-
tions. A third—and perhaps more fundamental—hurdle in 
initiating clinical trials in Europe with genetically modified 
cells is the bureaucratic burden imposed by regulation. In 
2004, the European Clinical Trials Directive 2001/20/EC 
(EU-CTD) was introduced in order to protect clinical trial 
subjects by establishing quality, safety, and ethical criteria 
of initiated trials. In current practice, this implies that a trial 
needs to be reviewed in each individual member state by 
both a research ethic committee and national competent 
authority. This process turned out to be suboptimal in daily 
practice. First, one could argue that a scientific and ethical 
judgment should be integrated in one review body, since 
the scientific merit of clinical research cannot be judged 
without an ethical evaluation and vice versa. In addition, 
leaving the organization of the review bodies to the individ-
ual member states leads to large inter-country differences 
and subsequent inconsistent evaluations (reviewed in [49]). 
Consequently, between 2007 and 2011, the number of clin-
ical trials conducted in the EU fell by 25 %, and the num-
ber of clinical trials applied for in 2007 (5000) dropped to 
3800 by 2011, with most studies being limited to one coun-
try. So despite a potential additional protection of subjects, 
the European Clinical Trial Directive seems to prohibit 
European citizens from accessing innovative therapies. In 
the USA, there is a more streamlined approach, with one 
nationally appointed service, namely the Department of 
Health and Human Services (DHHS) providing oversight 
of clinical trials. All investigators must comply with these 
regulations when conducting clinical gene therapy trials. 
Although precise numbers are absent, the general feeling 
among researchers in the field is that the time to approve a 
gene therapy protocol is shorter in the USA than it is in the 
EU. This may also be reflected by the already mentioned 
difference in numbers of clinical trials in the EU as com-
pared to the USA. Also, a trend toward increased clinical 
trials in areas with emerging economies such as Asia, South 
America, and Russia is acknowledged by the EU.
To diminish the time-consuming bureaucracy in the 
EU, a new legislation ‘Clinical Trial Regulation EU No 
536/2014’ was adopted on April 2014 and is scheduled to 
be implemented in May 2016. The objective is ‘to restore 
European Union’s competitiveness in clinical research and 
the development of new and innovative treatments and 
medicines for the ultimate benefit of patients.’ Indeed, they 
claim to make the process more transparent and faster, but 
the notion that a single research protocol still has to be 
judged both by a scientific committee of a reporting mem-
ber state and separately by a scientific committee of each 
individual member state makes one wonder whether this 
new legislation will truly lead to a reduction ‘in red tape’ 
and increase in trials. Obviously, the efficacy of this new 
legislation has to be evaluated—which will at least take 
another year—, but the lack of centralization of the process 
feels like a missed opportunity, not only with regard to the 
speed of the process, but also as an incentive for European 
researches to act as a united team.
Regardless of the reasons for the striking differences in 
the processes for clinical trials initiated in the USA versus 
Europe, it is clear that researchers who intend to translate 
their science into novel therapies for patients should still 
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mainly focus on the science around engineered cellular 
products. Additionally, researchers should also contribute 
to improving the regulatory, structural and financial corner-
stones for these novel treatments.
Concluding remarks
Designing novel concepts of allo-SCT by promoting the 
early reconstitution of innate immune cells complemented 
subsequently with ‘genetically engineered immunity’ by 
utilizing both, innate and adaptive, receptors has the poten-
tial to substantially reduce toxicity and provide a profound 
short- and long-term protection against cancer. Components 
of this concept can be utilized not only for hematological 
but also for solid malignancies and allow engineering of a 
diverse immune response against cancer. Bearing in mind 
that the associated treatment-related morbidity and mortal-
ity of the current state-of-the-art treatment for many poor 
risk hematological malignancies are substantial, regulatory, 
and financial requirements, for the implementation of novel 
innovative cellular designer drugs seem to be completely 
out of balance. With a treatment-related mortality of up to 
30 %, frequently accepted for many routinely performed 
allo-SCTs in 2015 worldwide, one might question whether 
current regulatory and financial hurdles compromise rather 
than protect the lives of our patients. Thus, controlling can-
cer needs not only an orchestrated action of immune cells 
expressing defined CARs, αβTCRs, γδTCRs, and other 
innate immune receptors, but also a well-balanced discus-
sion about regulatory and financial needs with all involved 
groups: the academic research community, pharmaceutical 
companies, authorities, and patients and their families—a 
major immunological and societal challenge.
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